Chuck joined Mersana in August 2020, bringing over 25 years of regulatory affairs, program leadership, and product development experience to the company. 

Prior to Mersana, he served as Vice President of Regulatory Strategy and Labeling at TESARO, Inc. before its acquisition by GlaxoSmithKline plc. While at TESARO, he was part of the research and development leadership team responsible for the strategic direction and management of the company’s entire portfolio. He was instrumental in the approval of niraparib in multiple indications and geographies. Previously, he worked as Executive Director of Regulatory Affairs at Cubist Pharmaceuticals, Inc. before its acquisition by Merck & Co. Inc. He has also served in regulatory strategy and affairs roles at Vertex Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc. and Acambis Inc.

Chuck holds a B.A. in biochemistry and molecular biology from Boston University.

Fun fact about Chuck: Chuck enjoys traveling with his family (including their dog, Nando), watching movies of all kinds and finding new hobbies (past hobbies have included mid-century folding cameras, renovating vintage lava lamps, and building a retro arcade game machine).